Literature DB >> 23382561

CD4+ T cell-depleted lymphocyte infusion impairs neither the recovery of recipient thymus nor the development of transplanted thymus.

Ming Shi1, Ming Li, Yunze Cui, Lin Liu, Yasushi Adachi, Susumu Ikehara.   

Abstract

Thymus transplantation, in conjunction with bone marrow transplantation (BMT), has been attracting attention for the treatment of various diseases. Recently, donor lymphocyte infusion (DLI) has been used as a helpful tool for establishing donor chimerism and preventing a relapse of leukemia/lymphoma. However, the effects of DLI on transplanted and recipient thymuses have not been explored. We therefore performed DLI in the intrabone marrow-BMT + thymus transplantation setting. We have found that DLI leads to derangements in both recipient thymuses and transplanted thymuses; by 2 wk after BMT, we saw a decrease in total cell number, a lower percentage of CD4(+)CD8(+) cells, and the obliteration of the thymic corticomedullary junction. Four weeks later, the thymic impairment became more serious. However, when we depleted the CD4(+) T cells (CD4(-)-DLI), the recipient thymic recovery and transplanted thymic development were significantly restored by the treatment. In addition, there were much greater levels of TNF-α and Fas ligand, and a lower percentage of regulatory T cells in the DLI group than in the CD4(-)-DLI group. These findings indicate that inflammation induced by DLI, especially by CD4(+) T cells, plays a crucial role in the thymic impairment.

Entities:  

Mesh:

Year:  2013        PMID: 23382561      PMCID: PMC3586976          DOI: 10.4049/jimmunol.1201605

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  36 in total

1.  Allogeneic bone marrow transplantation (BMT) for refractory Behçet's disease with severe CNS involvement.

Authors:  A M Marmont; F Gualandi; G Piaggio; M Podestà; M Teresa van Lint; A Bacigalupo; F Nobili
Journal:  Bone Marrow Transplant       Date:  2006-06       Impact factor: 5.483

2.  Analyses of very early hemopoietic regeneration after bone marrow transplantation: comparison of intravenous and intrabone marrow routes.

Authors:  Qing Li; Hiroko Hisha; Ryoji Yasumizu; Tian-Xue Fan; Guo-Xiang Yang; Qiang Li; Yun-Ze Cui; Xiao-Li Wang; Chang-Ye Song; Satoshi Okazaki; Tomomi Mizokami; Wen-Hao Cui; Kequan Guo; Ming Li; Wei Feng; Junko Katou; Susumu Ikehara
Journal:  Stem Cells       Date:  2007-02-22       Impact factor: 6.277

3.  Donor T-cell alloreactivity against host thymic epithelium limits T-cell development after bone marrow transplantation.

Authors:  Mathias M Hauri-Hohl; Marcel P Keller; Jason Gill; Katrin Hafen; Esther Pachlatko; Thomas Boulay; Annick Peter; Georg A Holländer; Werner Krenger
Journal:  Blood       Date:  2007-01-09       Impact factor: 22.113

4.  Differential effects of anti-Fas ligand and anti-tumor necrosis factor alpha antibodies on acute graft-versus-host disease pathologies.

Authors:  K Hattori; T Hirano; H Miyajima; N Yamakawa; M Tateno; K Oshimi; N Kayagaki; H Yagita; K Okumura
Journal:  Blood       Date:  1998-06-01       Impact factor: 22.113

5.  Levels of soluble FasL and FasL gene expression during the development of graft-versus-host disease in DLT-treated patients.

Authors:  H Das; S Imoto; T Murayama; K Kajimoto; T Sugimoto; T Isobe; T Nakagawa; R Nishimura; T Koizumi
Journal:  Br J Haematol       Date:  1999-03       Impact factor: 6.998

6.  Treatment of autoimmune diseases in MRL/lpr mice by allogenic bone marrow transplantation plus adult thymus transplantation.

Authors:  N Hosaka; T Ryu; T Miyake; W Cui; T Nishida; T Takaki; M Inaba; S Ikehara
Journal:  Clin Exp Immunol       Date:  2007-03       Impact factor: 4.330

7.  The effect of thymic function on immunocompetence following bone marrow transplantation.

Authors:  K Weinberg; G Annett; A Kashyap; C Lenarsky; S J Forman; R Parkman
Journal:  Biol Blood Marrow Transplant       Date:  1995-11       Impact factor: 5.742

8.  A new strategy for treatment of malignant tumor: intra-bone marrow-bone marrow transplantation plus CD4- donor lymphocyte infusion.

Authors:  Yasuhiro Suzuki; Yasushi Adachi; Keizo Minamino; Yuming Zhang; Masayoshi Iwasaki; Keiji Nakano; Yasushi Koike; Susumu Ikehara
Journal:  Stem Cells       Date:  2005-03       Impact factor: 6.277

9.  Allogeneic intrabone marrow-bone marrow transplantation plus donor lymphocyte infusion suppresses growth of colon cancer cells implanted in skin and liver of rats.

Authors:  Yasushi Koike; Yasushi Adachi; Yasuhiro Suzuki; Masayoshi Iwasaki; Naoko Koike-Kiriyama; Keizo Minamino; Keiji Nakano; Hiromi Mukaide; Akio Shigematsu; Yasuhiko Kiyozuka; Airo Tubura; Yasuo Kamiyama; Susumu Ikehara
Journal:  Stem Cells       Date:  2007-02       Impact factor: 6.277

10.  Review of 54 patients with complete DiGeorge anomaly enrolled in protocols for thymus transplantation: outcome of 44 consecutive transplants.

Authors:  M Louise Markert; Blythe H Devlin; Marilyn J Alexieff; Jie Li; Elizabeth A McCarthy; Stephanie E Gupton; Ivan K Chinn; Laura P Hale; Thomas B Kepler; Min He; Marcella Sarzotti; Michael A Skinner; Henry E Rice; Jeffrey C Hoehner
Journal:  Blood       Date:  2007-02-06       Impact factor: 22.113

View more
  1 in total

1.  Gr-1 Ab administered after bone marrow transplantation plus thymus transplantation suppresses tumor growth by depleting granulocytic myeloid-derived suppressor cells.

Authors:  Ming Shi; Ming Li; Yunze Cui; Yasushi Adachi; Susumu Ikehara
Journal:  PLoS One       Date:  2014-05-21       Impact factor: 3.240

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.